Tell us who you want to see featured on the list – and why, using the link below. We are counting on you to nominate your collaborators, colleagues and peers.
Sitting Down With… Abhijit Mukherjee, COO of Dr. Reddy's Laboratories, India
Why stop at biosimilar when you can be biobetter?
The FDA aims to reduce drug prices with a more competitive market - and generics are key.
John Lambert talks antibody-drug conjugates and his involvement with Kadcyla.
Will a pilot project to prequalify “generic” biologics improve safe access to medicines?
We forge ahead to celebrate the fantastic individuals involved in bettering the pharma industry.
Surface plasmon resonance has become a go-to tool for biotherapeutic characterization.
President Trump has the opportunity to get healthcare moving by boosting biogeneric use.
Sitting Down With... Fiona Greer, a biosimilar guru from SGS.
Could manufacturers based in Russia be well placed to develop cheaper biopharmaceuticals?
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.